245 related articles for article (PubMed ID: 29169183)
1. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
Craze ML; Cheung H; Jewa N; Coimbra NDM; Soria D; El-Ansari R; Aleskandarany MA; Wai Cheng K; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Br J Cancer; 2018 Jan; 118(2):258-265. PubMed ID: 29169183
[TBL] [Abstract][Full Text] [Related]
2. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
El Ansari R; Craze ML; Miligy I; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res; 2018 Mar; 20(1):21. PubMed ID: 29566741
[TBL] [Abstract][Full Text] [Related]
3. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC.
Liu W; Le A; Hancock C; Lane AN; Dang CV; Fan TW; Phang JM
Proc Natl Acad Sci U S A; 2012 Jun; 109(23):8983-8. PubMed ID: 22615405
[TBL] [Abstract][Full Text] [Related]
5. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.
Ding J; Kuo ML; Su L; Xue L; Luh F; Zhang H; Wang J; Lin TG; Zhang K; Chu P; Zheng S; Liu X; Yen Y
Carcinogenesis; 2017 May; 38(5):519-531. PubMed ID: 28379297
[TBL] [Abstract][Full Text] [Related]
6. PYCR in Kidney Renal Papillary Cell Carcinoma: Expression, Prognosis, Gene Regulation Network, and Regulation Targets.
Shao Z; Lu L; Cui Y; Deng L; Xu Q; Liang Q; Lu X; Zhang J; Chen J; Situ Y
Front Biosci (Landmark Ed); 2022 Dec; 27(12):336. PubMed ID: 36624948
[TBL] [Abstract][Full Text] [Related]
7. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix.
Kay EJ; Paterson K; Riera-Domingo C; Sumpton D; Däbritz JHM; Tardito S; Boldrini C; Hernandez-Fernaud JR; Athineos D; Dhayade S; Stepanova E; Gjerga E; Neilson LJ; Lilla S; Hedley A; Koulouras G; McGregor G; Jamieson C; Johnson RM; Park M; Kirschner K; Miller C; Kamphorst JJ; Loayza-Puch F; Saez-Rodriguez J; Mazzone M; Blyth K; Zagnoni M; Zanivan S
Nat Metab; 2022 Jun; 4(6):693-710. PubMed ID: 35760868
[TBL] [Abstract][Full Text] [Related]
8. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.
Green AR; Aleskandarany MA; Agarwal D; Elsheikh S; Nolan CC; Diez-Rodriguez M; Macmillan RD; Ball GR; Caldas C; Madhusudan S; Ellis IO; Rakha EA
Br J Cancer; 2016 Apr; 114(8):917-28. PubMed ID: 26954716
[TBL] [Abstract][Full Text] [Related]
9. c-Myc Overexpression Promotes Oral Cancer Cell Proliferation and Migration by Enhancing Glutaminase and Glutamine Synthetase Activity.
Wang T; Cai B; Ding M; Su Z; Liu Y; Shen L
Am J Med Sci; 2019 Sep; 358(3):235-242. PubMed ID: 31324362
[TBL] [Abstract][Full Text] [Related]
10. Proline metabolism and cancer: emerging links to glutamine and collagen.
Phang JM; Liu W; Hancock CN; Fischer JW
Curr Opin Clin Nutr Metab Care; 2015 Jan; 18(1):71-7. PubMed ID: 25474014
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
[TBL] [Abstract][Full Text] [Related]
12. Genetic analysis of Pycr1 and Pycr2 in mice.
Stum MG; Tadenev ALD; Seburn KL; Miers KE; Poon PP; McMaster CR; Robinson C; Kane C; Silva KA; Cliften PF; Sundberg JP; Reinholdt LG; John SWM; Burgess RW
Genetics; 2021 May; 218(1):. PubMed ID: 33734376
[TBL] [Abstract][Full Text] [Related]
13. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2.
Xiao D; Ren P; Su H; Yue M; Xiu R; Hu Y; Liu H; Qing G
Oncotarget; 2015 Dec; 6(38):40655-66. PubMed ID: 26528759
[TBL] [Abstract][Full Text] [Related]
14. Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis.
Sun T; Song Y; Yu H; Luo X
Cancer Biol Ther; 2019; 20(6):760-773. PubMed ID: 30810442
[TBL] [Abstract][Full Text] [Related]
15. Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.
Loayza-Puch F; Rooijers K; Buil LC; Zijlstra J; Oude Vrielink JF; Lopes R; Ugalde AP; van Breugel P; Hofland I; Wesseling J; van Tellingen O; Bex A; Agami R
Nature; 2016 Feb; 530(7591):490-4. PubMed ID: 26878238
[TBL] [Abstract][Full Text] [Related]
16. The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer.
Masisi BK; El Ansari R; Alfarsi L; Craze ML; Jewa N; Oldfield A; Cheung H; Toss M; Rakha EA; Green AR
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439127
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic modification facilitates proline synthase PYCR1 aberrant expression in gastric cancer.
Xiao S; Yao X; Ye J; Tian X; Yin Z; Zhou L
Biochim Biophys Acta Gene Regul Mech; 2022 Aug; 1865(6):194829. PubMed ID: 35654390
[TBL] [Abstract][Full Text] [Related]
18.
Christensen EM; Bogner AN; Vandekeere A; Tam GS; Patel SM; Becker DF; Fendt SM; Tanner JJ
J Biol Chem; 2020 Dec; 295(52):18316-18327. PubMed ID: 33109600
[TBL] [Abstract][Full Text] [Related]
19. Structure, biochemistry, and gene expression patterns of the proline biosynthetic enzyme pyrroline-5-carboxylate reductase (PYCR), an emerging cancer therapy target.
Bogner AN; Stiers KM; Tanner JJ
Amino Acids; 2021 Dec; 53(12):1817-1834. PubMed ID: 34003320
[TBL] [Abstract][Full Text] [Related]
20. The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.
El-Ansari R; Craze ML; Alfarsi L; Soria D; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 May; 175(1):27-38. PubMed ID: 30671766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
